Clindamycin News and Research

RSS

Valeant develops an acne drug with a low concentration of BPO combined with clindamycin

One of the most widely prescribed drugs for acne vulgaris is benzoyl peroxide (BPO). However, at concentrations of 5-10%, BPO has the potential for skin irritation and dryness leading to poor patient compliance. Increasingly, BPO is combined with clindamycin in a fixed combination where the efficacy effects of the two ingredients are synergistic.

8 Sep 2009

Mylan Pharmaceuticals markets FDA approved first generic version of Sanofi Aventis' BenzaClin

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International. The preparation is the first generic version of Sanofi Aventis' BenzaClin(R) to be approved by the U.S. Food and Drug Administration (FDA).

27 Aug 2009

The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women

Antimicrobial treatments for bacterial vaginosis (BV) are effective, but taking lactobacillus tablets alongside metronidazole antibiotic therapy increases effectiveness over taking this antibiotic alone, according to a Cochrane Systematic Review. The researchers also concluded that intravaginal lactobacillus was as effective as oral metronidazole, although they did note unexplained drop-outs from the trials.

7 Jul 2009

Discovery of better treatment for bacterial pneumonia

Scientists at St. Jude Children's Research Hospital have demonstrated a more effective treatment for bacterial pneumonia following influenza.

9 Jan 2009

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.

26 Oct 2008

Group B streptococcus has decreased among newborns, increased among adults

Group B streptococcus, a major cause of serious infections, declined about 25 percent among infants younger than 7 days from 1999 to 2005, but increased nearly 50 percent among persons 15 to 64 years old, according to a study in the May 7 issue of JAMA, the Journal of the American Medical Association.

6 May 2008

Vaginal probiotic product reduce recurrence rate of bacterial vaginosis

A newly published double blind, randomised, placebo controlled study(1) shows that EcoVag, a patented vaginal probiotic product from the Danish company, Bifodan, significantly reduces the recurrence rate of Bacterial Vaginosis (BV) following antibiotic treatment.

31 Jan 2008

Immtech and BioAlliance sign agreement on Pafuramidine for African sleeping sickness

Immtech Pharmaceuticals has announced that the Company has granted an exclusive license to BioAlliance Pharma SA to commercialize Immtech's oral drug, pafuramidine maleate (pafuramidine), in Europe for the treatment of pneumocystis pneumonia (PCP) in AIDS patients and for the treatment of Human African trypanosomiasis, also known as African sleeping sickness.

5 Dec 2007

Antibiotic-resistant MRSA all too common

Researchers in the U.S. say that methicillin-resistant Staphylococcus aureus or MRSA is the most common cause of skin and soft-tissue infections among patients presenting in emergency rooms across the country.

20 Aug 2006

Dodgy Chinese antibiotic kills at least 7

According to the Ministry of Health in China at least 7 deaths have now been linked to the injectable antibiotic clindamycin phosphate glucose.

10 Aug 2006

Chinese antibiotic suspected of being a killer jab

An antibiotic which is suspected to be responsible for three deaths has been banned in China and all stocks have been recalled.

6 Aug 2006

New treatments for common vaginal infection being studied

Whether a two-week regimen using a stainless steel douching device can eradicate the most common vaginal infection is under study at the Medical College of Georgia.

9 May 2005

Researchers make gains in understanding antibiotic resistance

Howard Hughes Medical Institute researchers chiseling away at the problem of antibiotic resistance now have a detailed explanation of how the drugs' main cellular target in bacteria evolves to become resistant to some of these medications.

22 Apr 2005

People could be exposed to antibiotic-resistant bacteria from breathing air from swine feeding facilities

People could be exposed to antibiotic-resistant bacteria from breathing the air from concentrated swine feeding facilities, according to researchers at the Johns Hopkins Bloomberg School of Public Health.

4 Dec 2004

FDA approval of cream to treat bacterial vaginosis

KV Pharmaceutical Company has announced that it has received approval from the United States Food and Drug Administration (FDA) to market Clindesse (clindamycin phosphate) Vaginal Cream, 2%, a single-dose prescription cream therapy indicated to treat bacterial vaginosis ("BV").

3 Dec 2004

Study results suggest that metronidazole and clindamycin differ in their effects on microbes in women with bacterial vaginosis

In the first study to directly compare the emergence of antibiotic resistance following topical treatment between two antibiotics routinely prescribed for a common vaginal infection, researchers from the Magee-Womens Research Institute have found antibiotic-resistant bacteria more likely to develop with the drug clindamycin than metronidazole.

1 Nov 2004

New Drug Application for Velac accepted for filing by the FDA

Connetics Corporation, a specialty pharmaceutical company focused on dermatology, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for Velac

25 Oct 2004

Drug-resistant bacteria increasingly causing infections in healthy people

An emerging form of so-called "flesh-eating bacteria" is caused by a strain that is resistant to standard first-line antibiotics. The same type of bacteria, methicillin-resistant Staphylococcus aureus (MRSA) is causing record numbers of less-serious skin infections in children and also is emerging as a cause of pneumonia, which can be deadly

30 Sep 2004

Severe infections with flesh-eating bacteria are considerably more common than expected

In an EU project covering 11 countries, headed by Lund University in Sweden, it was calculated that some 1,000 cases would be found over an initial 1½-year period. Fully 5,000 were identified.

16 Sep 2004

How to avoid MRSA infection

Staph bacteria are not uncommon in health care settings. In fact, they account for a large number of hospital-related infections each year.

3 Aug 2004